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Introduction: Little is known about the natural history of malignant
solitary pulmonary nodules (SPN). Experts’ beliefs may help fill
these knowledge gaps and explain variation in clinical practices.
Methods: Using a modified Delphi process, we surveyed a group of
lung cancer experts about tumor growth, disease progression, and
prognosis in patients with malignant SPN. After completing the first
survey, experts were given the opportunity during a second survey
to revise their responses in light of their peers’ beliefs.
Results: The response rate was 100% (14 of 14) for both surveys.
There was consensus that disease progression depends on the tumor
growth rate, that survival for patients with untreated lung cancer is
approximated by a declining exponential function, and that treat-
ment is delayed by approximately 1 tumor volume doubling time
(TVDT) in patients who undergo a period of “watchful waiting.”
Just over half of experts (8 of 14) agreed that lung cancer progresses
in three steps (from local to regional to distant disease), whereas
43% (6 of 14) preferred a 2-step model (from local to systemic
disease). Likewise, 64% of experts (9 of 14) believed that malignant
nodules grow exponentially, whereas 36% (5 of 14) believed that
growth is slower than exponential. Experts’ estimates of the risk of
disease progression during a period of observation lasting 1 TVDT
varied from 1 to 50%. Estimates of 5-year survival for patients in
whom diagnosis and treatment were delayed by 1 TVDT varied
between 40% and 80%.
Conclusions: There is substantial variability in experts’ beliefs about
the natural history of untreated, malignant SPN. Different beliefs may
be partly responsible for variation in management practices.
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The solitary pulmonary nodule (SPN) is a common andchallenging clinical problem. Although evidence-based
guidelines and decision analytic models have been developed
to help guide clinical decisions about diagnosis and treatment
of patients with SPN, these tools are limited by gaps in our
current knowledge about the natural history of lung cancer.1,2
Little is known about the natural history of untreated, malig-
nant lung nodules. More specifically, we know little about the
risk of disease progression during a period of diagnostic delay
or planned observation. This limits clinicians’ ability to
counsel patients about the risks associated with a strategy of
“watchful waiting.” In the absence of empirical data, experts’
beliefs may be useful to clinicians and developers of decision
aids by filling some knowledge gaps.
The Delphi method was developed in the 1950s by the
RAND Corporation to elicit reliable consensus opinion
among a group of experts.3 The technique has been adapted in
numerous ways, but centers around repeated questioning of
experts, usually in the form of a survey or individual inter-
views, with feedback on peer responses or thought processes
provided between rounds of questioning. The method aims to
promote individual thinking by avoiding confrontation be-
tween experts, while guiding opinion towards a consensus.
The Delphi method has been used to elicit expert consensus
about a wide variety of medical topics,4,5 including manage-
ment of spontaneous pneumothorax.6
In this study, we employed a modified Delphi technique
to evaluate expert agreement with assumptions about the
natural history of lung cancer, and to measure experts’ beliefs
about tumor growth, disease progression, and survival in
patients with a malignant SPN.
METHODS
We invited leaders from the Thoracic Oncology Net-
work of the American College of Chest Physicians to partic-
ipate in an expert panel. Follow-up emails were sent to experts
who did not respond to the initial invitation. This study was
approved by the Institutional Review Board of Stanford Univer-
sity. All participants provided informed consent.
Survey
We measured experts’ beliefs about malignant SPN
through two rounds of an on-line survey (Appendix). In the
first round, we asked experts to provide estimates of median
tumor volume doubling times (TVDT), rates of progression
from resectable to unresectable disease, and 5-year survival
for hypothetical patients with malignant nodules. We also
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asked experts to indicate their level of agreement with as-
sumptions about tumor growth rates, disease progression, and
survival by using a 5-point Likert scale. We developed survey
items based on assumptions from a natural history model of
lung cancer.7,8 We emphasize that the survey was designed to
measure beliefs, not to test knowledge.
In the second round of the survey, we again asked experts
to indicate their agreement with the assumptions, this time while
considering their peers’ responses from the previous round.
Adjacent to each item, we embedded a bar chart depicting the
distribution of first-round responses and an arrow indicating
where the participant’s previous response fell within that distri-
bution (Appendix). To maintain confidentiality, each participant
was sent a unique round 2 survey with only his or her own
responses indicated. Participants could keep their responses the
same, or revise them in light of their peers’ responses.
We also asked multiple choice-type questions about sev-
eral assumptions in the second round survey. We asked experts
to choose between several models of tumor growth (constant,
increasing, or decreasing rate), disease progression (3-step, from
local to regional to distant, or 2-step, from local to systemic), and
survival (quadratic, linear, or exponential curves). We also asked
experts to estimate the approximate tumor diameter at which
death would occur, on average, in a sample of patients with
untreated non-small cell lung cancer (NSCLC).
Statistical Analyses
For Likert scale items, we report the number of experts
who agreed or disagreed with each assumption. For estimates,
we report range and median values. When we asked experts
to estimate values under two different conditions, we calcu-
lated the difference between each expert’s estimates. We
report ranges and median values of these differences. We
report detailed results from the second and final survey round
only, unless otherwise noted.
RESULTS
The response rate was 100% (14 of 14) in both rounds
of the survey. The panel included 9 specialists in pulmonary
medicine, 4 thoracic surgeons, and 1 pathologist.
Tumor Growth
There was limited consensus among the experts regard-
ing growth of malignant nodules. In the first survey round, a
clear majority of experts (12 of 14) agreed that a 1-cm nodule
has doubled in volume 30 times, an assumption consistent
with exponential growth. When asked explicitly whether they
believed that tumor growth was exponential, 62% (8 of 13)
favored this model (Figure 1). When asked to select the tumor
growth model with which they most agreed, a majority (9 of
14) chose exponential growth (corresponding to doubling in
volume at a constant rate), but a sizable minority (5 of 14)
believed that the rate of growth decreased over time.
Disease Progression
There was clear consensus that the probability of disease
progression depends on the tumor growth rate, but none of the
experts agreed that the monthly probability of progression from
local to regional disease equals that for progression from re-
gional to distant disease (Figure 1). Experts appeared to favor a
3-step model of disease progression, with which 9 of 14 agreed.
When forced to choose between the 3-step and 2-step models, a
slim majority (8 of 14) selected the 3-step model as the most
appropriate, whereas a sizable minority (6 of 14) selected the
2-step model. In subsequent discussions with several panel
members, they suggested that lung cancer progression may be a
2-step or 3-step process in different patients.
There was clear consensus that treatment is delayed by
approximately 1 TVDT in patients who undergo a period of
observation, or “watchful waiting,” during their evaluation for
lung cancer (Figure 1). However, opinion varied widely as to the
consequences of such a delay. Experts’ estimates of the proba-
bility of progressing from resectable to unresectable disease
during a delay lasting 1 TVDT ranged from 1 to 50% (Table 1).
Survival
There was consensus that in a sample of patients with
potentially resectable NSCLC, survival is approximated by a
simple declining exponential function (Figure 1). Four ex-
perts reported that survival was best approximated by a
quadratic function, and none chose a linear function to de-
FIGURE 1. Expert Panel Agreement
with Assumptions, Round 2. Expert
agreement with assumptions about
tumor growth, disease progression
and survival in patients with NSCLC,
after the second survey round. Re-
sponses of “Agree” and “Strongly
Agree” were combined, as were re-
sponses of “Disagree” and “Strongly
Disagree.” One expert did not pro-
vide a response to the final assump-
tion. NSCLC, non-small cell lung
cancer; TVDT, tumor volume dou-
bling time.
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scribe survival. Estimates of the probability of 5-year survival
with and without prompt treatment varied widely (Table 1).
The median difference between estimates of 5-year survival
with and without delayed treatment was 5% (range, 0–20%).
In an untreated patient with NSCLC, the median tumor
diameter at the time of death was believed to be 5 cm (range,
1–10 cm) (Table 1). Only four participants believed that the
average tumor diameter at the time of death was 10 cm
(Figure 1).
In general, responses changed only slightly from round 1
to round 2. In 4 of 7 questions that were asked in both rounds,
the median response (weak agreement) did not change, but a
small number of panelists modified their response by moving
closer to the median value. In one item (death after 40 dou-
blings in volume), 4 respondents moved closer to the median
response (neutral) and 1 moved away. In another item (lung
cancer progresses in 2 steps), 3 respondents moved away
from the median response (neutral) and 4 actually reversed
their positions (2 from agreement to disagreement and 2 from
disagreement to agreement). In one item (exponential
growth), the median value changed from neutral to weak
agreement after 3 participants modified their responses.
DISCUSSION
These results offer a first look at experts’ beliefs about
the natural history of malignant SPN. Although some con-
sensus existed among this small panel of experts, we ob-
served substantial variability in their beliefs. This variability
is likely explained in part by gaps in our current knowledge
about tumor biology and the natural history of lung cancer.
One simple model of natural history assumes that a
tumor begins as a single cell that measures 10 m in diameter
and grows exponentially (i.e., it doubles in volume at a
constant rate), and that on average, in the absence of treat-
ment, death occurs after 40 doublings in tumor volume, at
which time the tumor measures 10 cm in diameter.7,8 Our
results suggest that the face validity of this model is limited.
Our most striking finding is the variability in experts’
estimates of the risk of disease progression during a period of
observation lasting 1 TVDT, which ranged from 1 to 50%.
Estimates of 5-year survival for patients in whom diagnosis
and treatment were delayed also varied greatly (range, 40–
80%). Other areas of important disagreement include beliefs
about growth rates (exponential versus slower than exponen-
tial) and disease progression (3-steps versus 2-steps).
This study is limited by its small sample size, and the
results may not be generalizable to other groups of experts or
practicing clinicians. In most cases, we measured beliefs by
using a single item, and while items were not formally
validated, we believe that face validity was excellent.
In the absence of empirical data, beliefs about tumor
growth and disease progression may play a role in guiding
decisions about patient care. For example, clinicians who be-
lieve that malignant nodules are likely to progress from resect-
able to unresectable disease if diagnosis is delayed may be more
likely to refer for prompt surgical resection, rather than perform-
ing a biopsy or recommending follow-up with serial imaging
tests. Further research is needed to test this hypothesis and to
explore the relationship between physicians’ beliefs and prac-
tices. In particular, future work should examine beliefs about
tumor growth, disease progression, and survival in a sample of
practicing clinicians. In addition, this work should be coupled
with ongoing bench and translational research into the biology
of tumor growth and promoters of tumor spread.
In conclusion, this study represents the first survey, to our
knowledge, of experts’ beliefs about lung cancer growth, pro-
gression, and prognosis. Our results show that experts hold
different beliefs about the natural history of lung cancer and
suggest the possibility that these differences may partially ex-
plain variation in practices for managing patients with SPN.
ACKNOWLEDGMENTS
Supported by a grant from the National Cancer Insti-
tute (RO1 CA117340-2).
We are grateful for the assistance of Raphael Fleish-
man in creating the on-line surveys, and for the participation
of members of our expert panel.
TABLE 1. Expert Beliefs About Estimates of Tumor Growth,
Disease Progression, and Survival
Estimate n Median Range
Median tumor doubling time (mo)a 14 4 1.5–14
Probability of progression from
resectable to unresectable disease
during delay of 1 TVDTb
14 10% 1–50%
Average diameter (cm) of primary tumor
at time of deathc
13 5 1–10
Probability of 5-yr survival if nodule
resected without delayb
14 70% 60–80%
Probability of 5-yr survival if resection
delayed by 1 TVDTb
14 65% 40–80%
a For clinically-detected 1.6 cm NSCLC.
b For a 62-yr-old asymptomatic man with a 1.6 cm malignant solitary pulmonary
nodule due to NSCLC. No evidence of hilar or mediastinal lymph node enlargement on
chest CT.
c For a sample of patients with untreated NSCLC.
TVDT, tumor volume doubling time; NSCLC, non-small cell lung cancer; CT,
computed tomography.
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